Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: SARS-CoV-2
Interventions: mRNA-1273; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more

Conditions: Immunologic Deficiency Syndrome
Interventions: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™; Drug
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Birmingham, Alabama • North Palm Beach, Florida • Chicago, Illinois + 5 more

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Inotuzumab Ozogamicin, Lumbar Puncture, Ponatinib; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 283
States / cities: Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 175 more

Conditions: Dysosmia, Anosmia, Covid19
Interventions: Smell Retraining, Budesonide; Other · Drug
Lead sponsor: Amanda Stapleton; Other
Eligibility: 6 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections, AIDS
Interventions: Cholecalciferol (Vit D3); Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 24 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 1
Interventions: high GI meal, low GI meal, euglycemic insulin clamp, primed-variable insulin infusion; Other · Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Surgery
Interventions: 0.9% Saline warmed to 37 degrees Celsius, 0.9% Saline warmed to 24 degrees Celsius; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Primary Lateral Sclerosis, Nervous System Diseases, Hereditary Spastic Paraparesis
Interventions: No intervention; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 80 Years
Enrollment: 475 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 29
States / cities: Phoenix, Arizona • Orange, California • Jacksonville, Florida + 24 more

Conditions: Dementia
Interventions: Sleep Education Program; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prehypertension, Mild Hypertension
Interventions: Hawthorn, Placebo capsule; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: ESRD (End Stage Renal Disease)
Interventions: Not listed
Lead sponsor: HemoCept Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Erectile Dysfunction
Interventions: ASP-001, Viagra, ASP-001; Drug · Device
Lead sponsor: Aspargo Labs, Inc; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Chronic Pain
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 72 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Observation; Other
Lead sponsor: HIV Vaccine Trials Network; Network
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 7 more

Conditions: Premature; Infant, Light-for-dates
Interventions: Protein supplementation, Standard fortification; Dietary Supplement
Lead sponsor: University of Oklahoma; Other
Eligibility: 1 Minute to 1 Year
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Primary Immunodeficiency Disease
Interventions: IgG Next Generation (BT595); Biological
Lead sponsor: Biotest; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Centennial, Colorado + 6 more

Conditions: Uncomplicated Pregnancy, Abnormal Fetal Growth or Fluid
Interventions: Clinically-indicated ultrasound, Serial third trimester ultrasound; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Bellaire, Texas • Houston, Texas

Conditions: Hyperglycemia
Interventions: Oral water, Intravenous normal saline; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: 22q11 Deletion Syndrome
Interventions: NB-001, Placebo; Drug · Other
Lead sponsor: Nobias Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Osteoarthritis
Interventions: synovial fluid biomarker concentrations; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Urinary Tract Infections, Vaginal Flora Imbalance
Interventions: BioNourish; Device
Lead sponsor: Vaginal Biome Science; Other
Eligibility: Up to 89 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Healthy
Interventions: palbociclib commercial free base, famotidine, rabeprazole, antacid; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: Saakshi Khattri; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreas Cyst
Interventions: Blood, stool, pancreatic juice and cyst fluid collection, Pancreatic Surgery, Endoscopy Exam; Diagnostic Test · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

Vitamin D Dose Finding Study

Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus

Solution Temperature and Fluid Deficit During Hysteroscopy

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

Behavioral Sleep Intervention in Adult Family Homes

Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract

Fluid Status of Dialysis Subjects

Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.

Predicting Oxycodone Dose From Oral Fluid Drug Levels

A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials

Effect of Protein Intake on Preterm Infant Body Composition

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial

Oral Hydration for Mild to Moderate Hyperglycemia in the Emergency Department

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Reduction of Pro-Inflammatory Synovial Fluid Biomarkers in Osteoarthritis of the Knee With Alpha-2 Macroglobulin

Vaginal Care System for Menopausal Women With Urinary Tract Infections

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Molecular Detection of Advanced Neoplasia in Pancreatic Cysts